© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Nephros, Inc. (NEPH) stock surged +4.88%, trading at $4.08 on NASDAQ, up from the previous close of $3.89. The stock opened at $3.90, fluctuating between $3.85 and $4.15 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 20, 2026 | 3.90 | 4.15 | 3.85 | 4.08 | 34K |
| Feb 19, 2026 | 3.77 | 3.98 | 3.58 | 3.89 | 31.6K |
| Feb 18, 2026 | 4.06 | 4.28 | 3.58 | 3.77 | 162.19K |
| Feb 17, 2026 | 4.00 | 4.26 | 3.77 | 4.00 | 81.09K |
| Feb 13, 2026 | 3.76 | 4.10 | 3.67 | 4.10 | 11.13K |
| Feb 12, 2026 | 4.05 | 4.05 | 3.70 | 3.76 | 42.88K |
| Feb 11, 2026 | 3.89 | 4.10 | 3.89 | 4.04 | 27.81K |
| Feb 10, 2026 | 3.94 | 4.00 | 3.74 | 3.89 | 55.33K |
| Feb 09, 2026 | 3.93 | 4.26 | 3.82 | 4.02 | 92.27K |
| Feb 06, 2026 | 3.83 | 4.02 | 3.80 | 3.87 | 27.79K |
| Feb 05, 2026 | 4.07 | 4.25 | 3.80 | 3.88 | 33.63K |
| Feb 04, 2026 | 4.21 | 4.31 | 4.01 | 4.11 | 48.97K |
| Feb 03, 2026 | 4.59 | 4.61 | 4.21 | 4.26 | 27.42K |
| Feb 02, 2026 | 4.31 | 4.69 | 4.24 | 4.57 | 71.83K |
| Jan 30, 2026 | 4.36 | 4.45 | 4.28 | 4.31 | 18.86K |
| Jan 29, 2026 | 4.50 | 4.52 | 4.31 | 4.39 | 21.64K |
| Jan 28, 2026 | 4.45 | 4.57 | 4.38 | 4.51 | 21.18K |
| Jan 27, 2026 | 4.47 | 4.55 | 4.38 | 4.43 | 15.26K |
| Jan 26, 2026 | 4.68 | 4.68 | 4.31 | 4.49 | 39.81K |
| Jan 23, 2026 | 4.65 | 4.82 | 4.58 | 4.68 | 38.35K |
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
| Employees | 31 |
| Beta | 1.41 |
| Sales or Revenue | $14.24M |
| 5Y Sales Change% | 0.65% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |